An Update on The Economic Impact of Adult Immunisation

By Staff Writer

April 24, 2024

Introduction: The Value of Adult Immunisation in Health Economics

In the face of mounting pressures on global healthcare systems, adult immunisation programmes emerge as a beacon of fiscal responsibility and preventative wisdom. Recent research from the Office of Health Economics (OHE) has illuminated the substantial economic benefits these programs offer across ten diverse countries including Australia, Brazil, Germany, South Africa, Thailand, and the United States. With a return on investment of up to 19 times the initial outlay, the impact of adult immunisation stands as an exemplar of preventive healthcare, contributing to the development of a stronger and more resilient society.

Figure 1. Ten Countries Selected for this Analysis.

The Burden of Vaccine-Preventable Diseases

Vaccine-preventable diseases continue to exert a significant toll on adult populations worldwide. The OHE research underscores the heavy impact of conditions like seasonal influenza, pneumococcal disease, and others on healthcare systems. Adult immunisation programs offer a formidable shield against these diseases, averting severe health outcomes and mortality, especially among the elderly and those with chronic conditions.

Adult Immunisation Economic Impact

The economic modelling conducted by the OHE reveals that adult immunisation programs are not only health-preserving but also cost-saving. By preventing hospitalisations and emergency care, these programs can lead to net cost savings for healthcare systems. For instance, one full vaccination course can yield up to $4637 in net monetary benefits per individual.

Societal and Productivity Gains

Beyond healthcare savings, adult immunisation programs contribute to societal wealth. By preventing disease, they enable individuals to maintain productivity, reducing the economic burden on caregivers and the wider community. This aligns with the broader goals of health and economic equity, particularly benefiting underserved communities.

Figure 2. Percentage of Countries for with Evidence of Positive Impact on Value

Recommendations and Future Directions

The OHE report culminates in key recommendations, advocating for a prevention-first approach and robust funding for adult immunisation. It calls for the expansion of these programs as part of a life-course immunisation strategy, emphasising the need for further research to fill existing evidence gaps and inform policy decisions.

Conclusion

Adult immunisation programs are a cornerstone of preventive healthcare, offering unmatched economic benefits. As healthcare systems confront increasing demands, these programs stand as a testament to the power of prevention, offering a sustainable path forward for societies worldwide

Reference url

Recent Posts

drug price comparison
 

Global Drug Price Gaps Demand Better Drug Pricing Analysis

💊 International drug price comparison reveal stark price gaps—the U.S. pays 4.2 times more for brand-name drugs than OECD peers.

But are these studies fueling a market collapse or opening a strategic opportunity for sustainable pricing in the U.S. and globally?

Discover the shortcomings of international pricing comparisons and how robust drug pricing analysis can help balance access, affordability, and profitability in a complex market.

#SyenzaNews #healthcare #pricing

NICE HealthTech Reforms
            

NICE HealthTech Reforms: Accelerating Digital Innovation in NHS and Global Healthcare Systems

🌐 Are you ready to witness a paradigm shift in digital health technology?

The National Institute for Health and Care Excellence (NICE) has announced transformative reforms aimed at accelerating the adoption of digital health innovations within the NHS. By focusing on cost-effectiveness rather than mere cost savings, these changes promise to streamline regulatory processes and enhance evaluations aligned with healthcare priorities.

Dive into this insightful article to explore how NICE’s reforms could reshape the future of healthcare systems globally!

#SyenzaNews #DigitalHealth #HealthEconomics #Innovation

BioNTech BMS collaboration
   

BioNTech BMS Collaboration: Pioneering Advances in Solid Tumor Treatment with BNT327

🚀 What could a groundbreaking partnership between BioNTech and Bristol-Myers Squibb mean for the future of solid tumor therapy?

Their collaboration on BNT327 is set to revolutionize immuno-oncology with promising early-phase trial results and a strategic investment of over $1.5 billion. This innovative bispecific antibody targets both PD-L1 and VEGF-A, indicating potential for enhanced patient outcomes in challenging cancers like small cell lung cancer and triple-negative breast cancer.

Curious about how this partnership could reshape cancer treatments? Dive into the full analysis!

#SyenzaNews #oncology #drugdevelopment #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.